Immunomodulatory_NP Effect_NP of_IN Zidovudine_NP (_( ZDV_NP )_) on_IN Cytotoxic_JJ T_NN Lymphocytes_NNS Previously_RB Exposed_JJ to_TO ZDV_NP In_IN a_DT previous_JJ study_NN ,_, zidovudine_NP (_( ZDV_NP )_) was_VBD shown_VBN to_TO cause_VB a_DT concentration-dependent_JJ inhibition_NN of_IN antigen-specific_JJ cytotoxic_JJ T-lymphocyte_NP (_( CTL_NP )_) clonal_JJ expansion_NN (_( S._NP Francke_NP ,_, C._NP G._NP Orosz_NP ,_, K._NP A._NP Hayes_NP ,_, and_CC L._NP E._NP Mathes_NP ,_, Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT 44:1900-1905_CD ,_, 2000_CD )_) ._SENT However_RB ,_, this_DT suppressive_JJ effect_NN was_VBD lost_VBN if_IN exposure_NN to_TO ZDV_NP was_VBD delayed_VBN for_IN 24_CD to_TO 48_CD h_NN during_IN the_DT antigen_NN sensitization_NN period_NN ,_, suggesting_VBG that_IN antigen-primed_JJ CTL_NP may_MD be_VB less_RBR susceptible_JJ than_IN naive_JJ T_NN lymphocytes_NNS to_TO the_DT suppressive_JJ effects_NNS of_IN ZDV_NP ._SENT The_DT present_JJ study_NN was_VBD undertaken_VBN to_TO determine_VB if_IN naive_JJ T_NN lymphocytes_NNS were_VBD more_RBR sensitive_JJ to_TO the_DT suppressive_JJ effects_NNS of_IN ZDV_NP than_IN T_NN lymphocytes_NNS previously_RB exposed_VBN to_TO antigen_NN ._SENT The_DT 50_CD %_NN inhibitory_JJ concentration_NN (_( IC50_NP )_) values_NNS of_IN ZDV_NP were_VBD determined_VBN on_IN naive_JJ and_CC antigen-primed_JJ T-cell_NN responses_NNS in_IN an_DT alloantigen_NN system_NN ._SENT Lymphocyte_NN cultures_NNS with_IN continuous_JJ antigen_NN exposure_NN (_( double_RB prime_JJ )_) were_VBD more_RBR resistant_JJ to_TO ZDV_NP suppression_NN (_( IC50_NP =_SYM 316_CD muM_NN )_) than_IN were_VBD naive_JJ lymphocytes_NNS (_( IC50_NP =_SYM 87.5_CD muM_NN )_) ._SENT Interestingly_RB ,_, lymphocytes_NNS that_WDT were_VBD antigen_NN primed_VBN but_CC deprived_VBN of_IN antigen_NN during_IN the_DT final_JJ 7_CD days_NNS of_IN culture_NN (_( prime/hold_NN )_) were_VBD exquisitely_RB sensitive_JJ to_TO ZDV_NP suppression_NN (_( IC50_NP =_SYM 29.3_CD muM_NN )_) ._SENT The_DT addition_NN of_IN 80_CD muM_NN ZDV_NP during_IN the_DT initial_JJ priming_NN of_IN the_DT single-prime_NN (_( prime/hold_NN )_) and_CC double-prime_NN cultures_NNS did_VBD not_RB select_VB for_IN a_DT more_RBR drug-resistant_JJ cell_NN population_NN ._SENT The_DT differences_NNS in_IN ZDV_NP sensitivities_NNS are_VBP likely_RB a_DT reflection_NN of_IN the_DT physiological_JJ properties_NNS of_IN the_DT lymphocytes_NNS related_VBN to_TO their_PP$ activation_NN state_NN ._SENT Zidovudine_NP (_( azidothymidine_NN ;_: ZDV_NP )_) ,_, in_IN single_JJ or_CC combination_NN therapy_NN ,_, is_VBZ one_CD of_IN the_DT major_JJ drugs_NNS used_VBN to_TO treat_VB AIDS_NP ._SENT However_RB ,_, its_PP$ positive_JJ therapeutic_JJ value_NN is_VBZ countered_VBN by_IN clinical_JJ side_NN effects_NNS and_CC the_DT development_NN of_IN drug_NN resistance_NN ._SENT ZDV_NP also_RB has_VBZ potentially_RB troubling_JJ properties_NNS affecting_VBG immune_JJ cell_NN functions_NNS ,_, such_JJ as_IN suppression_NN of_IN antigen-driven_JJ T-cell_NN proliferation_NN ,_, prolongation_NN of_IN the_DT cell_NN cycle_NN ,_, and_CC inhibition_NN of_IN a_DT number_NN of_IN other_JJ immunologic_JJ responses_NNS including_VBG lectin-_NN and_CC antigen-induced_JJ mitosis_NN ,_, mixed_JJ lymphocyte_NN culture_NN reactions_NNS ,_, and_CC induction_NN of_IN the_DT cytotoxic_JJ T-lymphocyte_NP (_( CTL_NP )_) response_NN ._SENT Mechanisms_NNS by_IN which_WDT ZDV_NP influences_VBZ cell_NN ,_, and_CC specifically_RB immune_JJ cell_NN ,_, physiology_NN are_VBP largely_RB unknown_JJ ,_, and_CC the_DT biologic_JJ relevance_NN of_IN these_DT effects_NNS in_IN vivo_JJ is_VBZ speculative_JJ ._SENT However_RB ,_, the_DT potential_JJ impact_NN of_IN ZDV_NP on_IN CTL-mediated_NP cytolysis_NN is_VBZ of_IN particular_JJ concern_NN given_VBN the_DT importance_NN of_IN these_DT cells_NNS in_IN combating_VBG human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) infection_NN ._SENT In_IN a_DT previous_JJ study_NN that_WDT used_VBD limiting_VBG dilution_NN analysis_NN ,_, we_PP reported_VBD that_IN ZDV_NP caused_VBD concentration-dependent_JJ inhibition_NN of_IN clonal_JJ expansion_NN of_IN antigen-specific_JJ CTL_NP ,_, suggesting_VBG that_IN the_DT basis_NN for_IN ZDV-related_JJ immunosuppression_NN is_VBZ stasis_NN of_IN T-cell_NN expansion_NN ._SENT In_IN this_DT study_NN the_DT estimated_JJ frequency_NN of_IN alloantigen-specific_JJ CTLs_NNS was_VBD profoundly_RB lower_JJR in_IN in_IN vitro_NN sensitization_NN assays_NNS ,_, where_WRB ZDV_NP was_VBD present_JJ during_IN primary_JJ antigen_NN exposure_NN ._SENT However_RB ,_, this_DT suppressive_JJ effect_NN was_VBD lost_VBN if_IN exposure_NN to_TO ZDV_NP was_VBD delayed_VBN for_IN 24_CD to_TO 48_CD h_NN during_IN the_DT antigen_NN sensitization_NN period_NN ._SENT The_DT results_NNS suggested_VBD that_IN antigen-primed_NP CTL_NP may_MD be_VB less_RBR susceptible_JJ to_TO the_DT suppressive_JJ effects_NNS of_IN ZDV_NP than_IN naive_JJ T_NN lymphocytes_NNS ._SENT The_DT objectives_NNS of_IN the_DT present_JJ study_NN were_VBD (_( i_NP )_) to_TO measure_VB the_DT sensitivity_NN of_IN naive_JJ T_NN lymphocytes_NNS to_TO the_DT suppressive_JJ effects_NNS of_IN ZDV_NP ,_, and_CC (_( ii_NNS )_) to_TO determine_VB if_IN T_NN cells_NNS sensitized_VBN to_TO antigen_NN in_IN the_DT presence_NN of_IN ZDV_NP generated_VBD CTL_NP with_IN greater_JJR resistance_NN to_TO ZDV_NP suppression_NN ._SENT In_IN order_NN to_TO explore_VB this_DT possibility_NN ,_, we_PP used_VBD a_DT 50_CD %_NN inhibitory_JJ concentration_NN (_( IC50_NP )_) assay_NN to_TO measure_VB the_DT relative_JJ suppressive_JJ effect_NN of_IN ZDV_NP on_IN naive_JJ and_CC primed_VBN CTL_NP ._SENT The_DT results_NNS suggest_VBP that_IN naive_JJ cytotoxic_JJ T_NN cells_NNS are_VBP two_CD to_TO five_CD times_NNS more_RBR sensitive_JJ to_TO the_DT inhibitory_JJ effects_NNS of_IN ZDV_NP than_IN are_VBP activated_VBN antigen-primed_JJ cells_NNS ._SENT However_RB ,_, previously_RB antigen-primed_JJ T_NN cells_NNS that_WDT were_VBD cultured_VBN without_IN antigen_NN but_CC given_VBN interleukin-2_NN (_( IL-2_NP )_) were_VBD shown_VBN to_TO have_VB increased_VBN sensitivity_NN to_TO ZDV_NP over_IN that_DT determined_VBN for_IN naive_JJ CTL_NP ._SENT Antigen_NN priming_NN in_IN the_DT presence_NN of_IN ZDV_NP did_VBD not_RB generate_VB a_DT cytotoxic_JJ T-cell_NN population_NN with_IN greater_JJR resistance_NN to_TO ZDV_NP suppression_NN ._SENT Mice_NNS ._SENT |_SYM Animal_NP studies_NNS were_VBD performed_VBN in_IN accordance_NN with_IN the_DT University_NP Laboratory_NP Animal_NP Care_NP and_CC Use_NP Committee_NP and_CC DHEW_NP publication_NN no_RB ._SENT NIH_NP 74-23_CD ,_, Guide_NP for_IN the_DT Care_NP and_CC Use_NP of_IN Laboratory_NP Animals_NPS ._SENT Six-_NN to_TO 8-week-old_JJ female_JJ DBA/2_NP (_( H-2d_NP ,_, Mlsa_NP )_) and_CC C57BL/6_NP (_( B6_NP ;_: H-2b_NP ,_, Mlsb_NP )_) mice_NNS were_VBD purchased_VBN from_IN Harlan_NP Sprague_NP Dawley_NP Inc._NP (_( Indianapolis_NP ,_, Ind._NP )_) ._SENT The_DT mice_NNS were_VBD housed_VBN in_IN a_DT laminar_JJ flow_NN cabinet_NN (_( animal_JJ storage_NN isolator_NN ;_: Nu_NP Aire_NP Inc._NP ,_, Plymouth_NP ,_, Minn._NP )_) in_IN groups_NNS of_IN 5_CD to_TO 10_CD animals_NNS per_IN cage_NN ._SENT Upon_IN arrival_NN ,_, all_DT mice_NNS were_VBD allowed_VBN a_DT 7-day_JJ period_NN of_IN acclimation_NN before_IN use_NN ._SENT Animals_NNS were_VBD sacrificed_VBN and_CC spleens_NNS were_VBD collected_VBN within_IN 2_CD weeks_NNS following_VBG the_DT acclimation_NN period_NN ._SENT ZDV_NP ._SENT |_SYM ZDV_NP was_VBD obtained_VBN from_IN the_DT AIDS_NP Research_NP and_CC Reference_NP Reagent_NP Program_NP ,_, Division_NP of_IN AIDS_NP ,_, National_NP Institute_NP of_IN Allergy_NP and_CC Infectious_NP Diseases_NPS (_( NIAID_NP )_) ,_, National_NP Institutes_NPS of_IN Health_NP (_( NIH_NP )_) ,_, as_IN a_DT lyophilized_VBN powder_NN and_CC stored_VBD light-protected_JJ at_IN room_NN temperature_NN ._SENT ZDV_NP was_VBD dissolved_VBN in_IN cell_NN culture_NN medium_NN for_IN in_IN vitro_NN studies_NNS ._SENT Cell_NN harvest_NN ,_, separation_NN ,_, and_CC culture_NN ._SENT |_SYM Intact_NN spleens_NNS from_IN mice_NNS euthanized_JJ in_IN a_DT standard_JJ CO2_NP chamber_NN were_VBD dispersed_VBN into_IN single-cell_NN suspensions_NNS of_IN splenocytes_NNS and_CC washed_VBN three_CD times_NNS in_IN sterile_JJ phosphate-buffered_JJ saline_NN ._SENT Tissue_NN culture_NN medium_NN was_VBD Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN supplemented_VBD with_IN 1.6_CD mM_NP l-glutamine_NN ,_, 0.27_CD mM_NP folic_JJ acid_NN ,_, 0.27_CD mM_NP l-asparagine_NN ,_, 0.55_CD mM_NP l-arginine_NN ,_, 10_CD mM_NP HEPES_NP buffer_NN ,_, 1.0_CD mM_NP sodium_NN pyruvate_NNS ,_, 100_CD U_NP of_IN penicillin-streptomycin/ml_NP (_( Gibco_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) ,_, 5_CD x_SYM 10-5_CD M_NP beta-mercaptoethanol_NP (_( Sigma_NP Chemical_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) ,_, and_CC 10_CD %_NN heat-inactivated_JJ fetal_JJ calf_NN serum_NN ,_, with_IN 10_CD IU_NP of_IN IL-2/ml_NP (_( Boehringer_NP Mannheim_NP )_) freshly_RB added_VBD ._SENT Study_NN design_NN ._SENT (_( i_NP )_) Animal_NP model_NN ._SENT |_SYM The_DT experimental_JJ model_NN for_IN testing_VBG T-cell_NN sensitivity_NN to_TO ZDV_NP is_VBZ based_VBN on_IN the_DT one-way_JJ mixed_JJ lymphocyte_NN response_NN (_( MLR_NP )_) between_IN the_DT major_JJ histocompatibility_NN complex-distinct_NN mouse_NN strains_VBZ C57BL6_NP (_( responder_NN )_) and_CC DBA_NP (_( stimulator_NN )_) ._SENT The_DT product_NN of_IN the_DT MLR_NP is_VBZ a_DT C57BL6_NP T-cell_NN culture_NN with_IN a_DT high_JJ frequency_NN of_IN DBA-specific_JJ cytotoxic_JJ T_NN cells_NNS ._SENT These_DT single-primed_JJ cells_NNS can_MD be_VB expanded_VBN by_IN restimulation_NN with_IN a_DT second_JJ round_NN of_IN antigen_NN treatment_NN (_( cocultivation_NN with_IN irradiated_JJ DBA_NP splenocytes_NNS [_SYM irrDBA_NN ]_SYM )_) to_TO generate_VB what_WP we_PP have_VBP termed_VBN double-prime_JJ cells_NNS ._SENT The_DT single-prime_NN cells_NNS from_IN the_DT MLR_NP can_MD be_VB maintained_VBN without_IN a_DT second_JJ round_NN of_IN antigen_NN exposure_NN by_IN cocultivation_NN with_IN irradiated_JJ autologous_JJ C57BL6_NP splenocytes_NNS ._SENT We_PP refer_VBP to_TO these_DT cell_NN preparations_NNS as_IN prime-and-hold_NN (_( prime/hold_NN )_) T_NN lymphocytes_NNS ._SENT Thus_RB ,_, depending_VBG on_IN the_DT stage_NN of_IN cell_NN stimulation_NN ,_, ZDV_NP sensitivity_NN can_MD be_VB evaluated_VBN in_IN three_CD populations_NNS of_IN T_NN cells_NNS :_: naive_JJ (_( fresh_JJ splenocytes_NNS from_IN C57BL6_NP mice_NNS )_) ,_, single_JJ primed_VBD (_( prime/hold_NN )_) ,_, or_CC double_RB primed_VBN ._SENT The_DT rationale_NN for_IN using_VBG prime/hold_NN and_CC double-prime_NN CTLs_NNS is_VBZ as_RB follows_VBZ :_: alloantigen-activated_JJ CTL_NP ,_, in_IN contrast_NN to_TO nonactivated_JJ CTL_NP precursors_NNS ,_, no_RB longer_RBR require_VB contact_NN with_IN specific_JJ alloantigens_NNS to_TO allow_VB lymphokine-mediated_JJ clonal_JJ expansion_NN and_CC subsequent_JJ detection_NN in_IN microcultures_NNS ._SENT Exposure_NN to_TO a_DT single_JJ round_NN of_IN allogeneic_JJ antigen_NN stimulation_NN ,_, however_RB ,_, leads_VBZ to_TO activation_NN of_IN only_RB a_DT fraction_NN of_IN all_DT antigen-specific_JJ cells_NNS ._SENT Subsequent_JJ reexposure_NN to_TO the_DT same_JJ antigen_NN (_( double_VB priming_VBG )_) increases_VBZ the_DT percentage_NN of_IN antigen-reactive_JJ cells_NNS by_IN two_CD mechanisms_NNS :_: (_( i_NP )_) clonal_JJ expansion_NN of_IN already_RB antigen_NN sensitized_VBD cells_NNS ,_, and_CC (_( ii_NNS )_) first-time_JJ activation_NN of_IN cells_NNS which_WDT did_VBD not_RB respond_VB to_TO the_DT antigen_NN during_IN the_DT first_JJ encounter_NN ._SENT (_( ii_NP )_) Experimental_NP design_NN ._SENT |_SYM The_DT experimental_JJ design_NN had_VBD five_CD arms_NNS ._SENT (_( a_DT )_) Arm_NP 1_CD (_( naive_NN CTL_NP )_) ._SENT |_SYM Naive_NP CTL_NP were_VBD fresh_JJ splenocytes_NNS from_IN C57BL6_NP mice_NNS placed_VBD directly_RB into_IN the_DT IC50_NP assay_NN ._SENT Briefly_RB ,_, 3_CD x_SYM 104_CD C57BL6_NP splenocytes/well_NP (_( responder_NN cells_NNS )_) were_VBD incubated_VBN for_IN 7_CD days_NNS with_IN 3_CD x_SYM 104_CD irrDBA-2_NN splenocytes/well_NN (_( sensitizing_VBG cells_NNS )_) in_IN U-bottom_NP 96-well_NP plates_NNS in_IN the_DT presence_NN of_IN ZDV_NP concentrations_NNS ranging_VBG between_IN 0_CD and_CC 1,000_CD muM_NN ._SENT Each_DT ZDV_NP concentration_NN was_VBD tested_VBN in_RB replicates_VBZ of_IN six_CD ._SENT (_( b_LS )_) Arm_NP 2_CD and_CC Arm_NP 4_CD (_( double_RB prime_JJ )_) ._SENT |_SYM For_IN the_DT double-primed_JJ CTL_NP cultures_NNS ,_, 105_CD C57BL6_NP splenocytes_NNS were_VBD incubated_VBN with_IN 105_CD irrDBA-2_JJ splenocytes_NNS for_IN a_DT period_NN of_IN 14_CD days_NNS at_IN 37C_JJ in_IN 10_CD %_NN CO2_NN in_IN the_DT presence_NN (_( Arm_NP 4_CD )_) or_CC absence_NN (_( Arm_NP 2_CD )_) of_IN 80_CD muM_NN ZDV_NP ._SENT This_DT concentration_NN of_IN ZDV_NP was_VBD selected_VBN based_VBN on_IN previous_JJ studies_NNS showing_VBG suppression_NN of_IN T-cell_NN responses_NNS ._SENT The_DT cultures_NNS were_VBD given_VBN 25_CD mul_NN of_IN fresh_JJ IL-2_NN containing_VBG growth_NN medium_NN after_IN 9_CD days_NNS of_IN culture_NN ._SENT For_IN Arm_NP 4_CD ,_, the_DT growth_NN medium_NN contained_VBD 80_CD muM_NN ZDV_NP ._SENT After_IN the_DT 14-day_JJ culture_NN period_NN ,_, effector_NN cells_NNS were_VBD harvested_VBN ,_, pooled_VBN ,_, and_CC then_RB distributed_VBN in_IN U-bottom_NP microculture_NN plates_NNS to_TO achieve_VB a_DT final_JJ concentration_NN of_IN 3_CD x_SYM 103_CD effector_NN cells/well_NN ._SENT In_IN preparation_NN for_IN the_DT IC50_NP assay_NN ,_, each_DT well_RB received_VBN 105_CD irrDBA-2_JJ splenocytes_NNS (_( second_JJ round_NN of_IN antigen_NN stimulation_NN )_) ._SENT The_DT IC50_NP assay_NN is_VBZ described_VBN below_RB ._SENT (_( c_LS )_) Arm_NP 3_CD and_CC Arm_NP 5_CD (_( prime_VB and_CC hold_VB )_) ._SENT |_SYM The_DT prime/hold_NN cultures_NNS were_VBD the_DT same_JJ as_IN the_DT double-prime_JJ cultures_NNS during_IN the_DT initial_JJ 14-day_JJ culture_NN period_NN ._SENT At_IN that_DT point_NN ,_, however_RB ,_, instead_RB of_IN adding_VBG irradiated_JJ DBA_NP cells_NNS ,_, these_DT cultures_NNS received_VBD 105_CD irradiated_JJ C57BL6_NP splenocytes/well_NN as_IN feeder_NN cells_NNS in_IN preparation_NN for_IN the_DT IC50_NP assay_NN ._SENT Arm_NN 5_CD contained_VBD 80_CD muM_NN ZDV_NP during_IN the_DT initial_JJ 14-day_JJ culture_NN ,_, while_IN Arm_NP 3_CD was_VBD grown_VBN without_IN ZDV_NP ._SENT IC50_JJ assay_NN ._SENT |_SYM The_DT IC50_NP assay_NN followed_VBD the_DT procedure_NN outlined_VBN in_IN Fig._NN ._SENT As_RB described_VBN above_RB ,_, the_DT C57BL6/irrDBA-2_NP allogeneic_JJ mouse_NN system_NN was_VBD used_VBN as_IN a_DT source_NN of_IN CTL_NP to_TO measure_VB the_DT in_IN vitro_NN effect_NN of_IN ZDV_NP on_IN CTL_NP effector_NN cells_NNS ._SENT The_DT assay_NN procedure_NN was_VBD adapted_VBN from_IN a_DT previously_RB described_VBN protocol_NN for_IN determining_VBG precursor_NN frequency_NN by_IN limiting_VBG dilution_NN analysis_NN ._SENT The_DT assay_NN measures_VBZ drug-mediated_JJ inhibition_NN of_IN in_IN vitro_NN sensitization_NN and_CC clonal_JJ expansion_NN of_IN C57BL6_NP splenocytes_NNS (_( effector_NN cells_NNS )_) in_IN response_NN to_TO irrDBA-2_JJ splenocytes_NNS (_( sensitizing_VBG cells_NNS )_) ._SENT By_IN calculating_VBG an_DT IC50_NN for_IN this_DT drug_NN effect_NN ,_, it_PP is_VBZ possible_JJ to_TO compare_VB the_DT relative_JJ sensitivities_NNS of_IN different_JJ subsets_NNS of_IN CTL_NP to_TO ZDV_NP and_CC other_JJ drugs_NNS ._SENT 51Cr_NP release_NN assay_NN ._SENT |_SYM A_DT 100-mul_NP volume_NN of_IN cell_NN suspension_NN from_IN each_DT well_NN was_VBD transferred_VBN to_TO V-bottom_NP microculture_NN plates_NNS containing_VBG 3_CD x_SYM 103_CD 51Cr-labeled_JJ P815_NP target_NN cells_NNS ._SENT The_DT assay_NN mixture_NN was_VBD incubated_VBN for_IN 5_CD h_NN at_IN 37C_JJ in_IN 5_CD %_NN CO2_NN and_CC then_RB assayed_VBN for_IN 51Cr_NP release_NN ._SENT P815_JJ cells_NNS (_( DBA-2_NP origin_NN ,_, H-2d_NP ,_, Mlsa_NP )_) ,_, the_DT target_NN for_IN the_DT CTL_NP assay_NN ,_, were_VBD propagated_VBN in_IN culture_NN medium_NN consisting_VBG of_IN equal_JJ parts_NNS of_IN Leibovitz_NP L-15_NP and_CC RPMI_NP 1640_CD ,_, 10_CD %_NN heat-inactivated_JJ fetal_JJ bovine_JJ serum_NN ,_, 100_CD IU_NP of_IN penicillin/ml_NN ,_, and_CC 100_CD mug_NN of_IN streptomycin/ml_NN at_IN 5_CD %_NN CO2_NN and_CC 37C_JJ ._SENT For_IN 51Cr_NP labeling_VBG ,_, a_DT cell_NN pellet_NN of_IN 3_CD x_SYM 106_CD P815_NP cells_NNS collected_VBN from_IN log-phase_NN cultures_NNS was_VBD resuspended_VBN in_IN 650_CD muCi_NNS of_IN Na51CrO4_NP (_( New_NP England_NP Nuclear_NP ,_, Boston_NP ,_, Mass._NP )_) in_IN a_DT total_JJ volume_NN of_IN approximately_RB 100_CD mul_NN ,_, incubated_VBN at_IN 37C_JJ ,_, 5_CD %_NN CO2_NN for_IN 2_CD h_NN ,_, washed_VBN at_IN least_JJS three_CD times_NNS in_IN phosphate-buffered_JJ saline_NN ,_, and_CC adjusted_VBN to_TO the_DT required_JJ cell_NN concentration_NN ._SENT Drug_NP IC50_NP determination_NN ._SENT |_SYM To_TO define_VB the_DT IC50_NP of_IN ZDV_NP ,_, data_NN points_NNS from_IN the_DT IC50_NP assay_NN were_VBD fitted_VBN to_TO the_DT logistic_JJ model_NN by_IN nonlinear_JJ regression_NN using_VBG the_DT computer_NN program_NN JUMP-IN_NP (_( SAS_NP Institute_NP Inc._NP )_) ._SENT The_DT logistic_JJ model_NN uses_VBZ the_DT formula_NN alpha_NN =_SYM theta1/[1_NN +_SYM theta2_JJ x_NN e(theta3_NN x_NN log_NN dose_NN )_) ]_SYM ,_, where_WRB alpha_NN was_VBD the_DT fitted_JJ log_NN dose_NN ,_, and_CC theta1_JJ ,_, theta2_JJ ,_, and_CC theta3_NN were_VBD adjustable_JJ parameters_NNS set_VBD initially_RB to_TO equal_VB 1_CD before_IN the_DT fitting_JJ iterations_NNS ,_, and_CC log_NN dose_NN was_VBD the_DT log10_NN of_IN the_DT ZDV_NP concentration_NN (_( in_IN micromolar_NN )_) used_VBN in_IN the_DT assay_NN ._SENT A_DT fitted_JJ curve_NN was_VBD plotted_VBN on_IN an_DT x-y_JJ axis_NN where_WRB alpha_NN was_VBD the_DT x_NN value_NN and_CC fa_NN was_VBD the_DT y_NN value_NN (_( see_VB Fig._NN )_) ._SENT fa_NN was_VBD defined_VBN as_IN the_DT fraction_NN affected_VBN by_IN drug_NN ,_, using_VBG the_DT formula_NN fa_NN =_SYM 1_CD -_: [_SYM (_( ZDV-treated_NP CTL_NP count_NN -_: spontaneous_JJ release_NN count)/(untreated_JJ CTL_NP count_NN -_: spontaneous_JJ release_NN count_VB )_) ]_SYM ._SENT The_DT median-effect_JJ log_NN concentration_NN and_CC its_PP$ corresponding_JJ 95_CD %_NN confidence_NN limits_NNS were_VBD determined_VBN by_IN plot_NN extrapolation_NN from_IN the_DT fa_NN value_NN of_IN 0.5_CD on_IN the_DT y_NP axis_NN (_( 50_CD %_NN effect_NN dose_NN )_) to_TO the_DT x_NN axis_NN (_( see_VB Fig._NN )_) ._SENT The_DT IC50_NP and_CC its_PP$ 95_CD %_NN confidence_NN limits_NNS were_VBD then_RB calculated_VBN from_IN the_DT anti-log_NN of_IN the_DT values_NNS extrapolated_VBN from_IN the_DT fitted_JJ curve_NN and_CC the_DT confidence_NN band_NN for_IN fa_NN ._SENT Determination_NN of_IN cell_NN viability_NN and_CC total_JJ cellularity_NN ._SENT |_SYM Cell_NN viability_NN and_CC cell_NN death_NN were_VBD assessed_VBN using_VBG the_DT trypan_JJ blue_JJ dye_NN exclusion_NN technique_NN ._SENT FIG._NN 1_CD ._SENT |_SYM CTL_NP culturing_VBG protocol_NN for_IN preparing_VBG alloantigen-reactive_JJ CTL_NP for_IN analysis_NN of_IN their_PP$ ZDV_NP sensitivity_NN in_IN the_DT IC50_NP assay_NN ._SENT CTL_NN culturing_VBG protocol_NN for_IN preparing_VBG alloantigen-reactive_JJ CTL_NP for_IN analysis_NN of_IN their_PP$ ZDV_NP sensitivity_NN in_IN the_DT IC50_NP assay_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Drug_NP inhibition_NN concentration_NN (_( IC50_NP )_) determination_NN ._SENT Drug_NN inhibition_NN concentration_NN (_( IC50_NP )_) determination_NN ._SENT To_TO define_VB the_DT IC50_NP of_IN ZDV_NP ,_, data_NN points_NNS were_VBD fitted_VBN to_TO a_DT logistic_JJ model_NN by_IN nonlinear_JJ regression_NN (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT The_DT log_NN dose_NN is_VBZ the_DT log10_NN of_IN the_DT ZDV_NP concentration_NN (_( micromolar_NN )_) used_VBN in_IN the_DT assay_NN ._SENT A_DT fitted_JJ line_NN was_VBD plotted_VBN on_IN an_DT x-y_JJ axis_NN ._SENT fa_NN was_VBD defined_VBN as_IN the_DT fraction_NN of_IN cytolysis_NN affected_VBN by_IN drug_NN ._SENT The_DT median-effect_JJ log_NN concentration_NN was_VBD determined_VBN from_IN the_DT fa_NN value_NN of_IN 0.5_CD on_IN the_DT y_NP axis_NN (_( 50_CD %_NN effect_NN dose_NN )_) to_TO the_DT x_NN axis_NN ._SENT The_DT median-effect_NN concentration_NN and_CC 95_CD %_NN confidence_NN limits_NNS were_VBD then_RB calculated_VBN from_IN the_DT anti-log_NN of_IN the_DT extrapolated_VBN value_NN ._SENT The_DT IC50_NP assay_NN can_MD be_VB used_VBN to_TO determine_VB the_DT relative_JJ inhibitory_JJ activity_NN of_IN antiviral_JJ drugs_NNS on_IN CTL_NP sensitization_NN ._SENT |_SYM An_NP in_IN vitro_NN system_NN to_TO generate_VB CTL_NP was_VBD used_VBN to_TO titrate_VB the_DT effects_NNS of_IN ZDV_NP on_IN the_DT CTL_NP response_NN ._SENT Figure_NN illustrates_VBZ the_DT results_NNS of_IN such_PDT an_DT assay_NN ._SENT A_DT constant_JJ number_NN of_IN effector_NN and_CC stimulator_NN cells_NNS in_IN replicates_VBZ of_IN six_CD were_VBD incubated_VBN with_IN various_JJ concentrations_NNS of_IN ZDV_NP during_IN antigen_NN priming_NN ._SENT As_IN the_DT ZDV_NP concentration_NN increased_VBD ,_, the_DT killing_VBG capacity_NN of_IN CTL_NP cultures_NNS was_VBD reduced_VBN in_IN a_DT concentration-dependent_JJ sigmoid_JJ pattern_NN ._SENT From_IN these_DT data_NNS ,_, the_DT IC50_NP value_NN for_IN ZDV_NP inhibition_NN of_IN CTL_NP activity_NN was_VBD computed_VBN by_IN determining_VBG the_DT median_JJ effective_JJ concentration_NN ._SENT Figure_NN is_VBZ an_DT example_NN showing_VBG a_DT best-fit_JJ plot_NN for_IN determining_VBG the_DT IC50_NP value_NN ._SENT Naive_JJ CTL_NN are_VBP more_RBR sensitive_JJ to_TO ZDV_NP inhibition_NN than_IN antigen-primed_JJ CTL_NP given_VBN a_DT second_JJ antigen_NN exposure_NN ,_, but_CC less_RBR sensitive_JJ than_IN antigen-primed_NP CTL_NP held_VBD in_IN culture_NN without_IN a_DT second_JJ antigen_NN stimulation_NN ._SENT |_SYM In_IN these_DT experiments_NNS we_PP compared_VBD the_DT inhibitory_JJ effects_NNS of_IN ZDV_NP on_IN naive_NN versus_CC double-prime_NN or_CC prime/hold_NN effector_NN cell_NN cultures_NNS ._SENT Results_NNS of_IN five_CD independent_JJ experiments_NNS are_VBP shown_VBN in_IN Table_NP ._SENT Individual_JJ rows_NNS indicate_VBP experiments_NNS performed_VBN at_IN the_DT same_JJ time_NN ._SENT The_DT IC50_NP values_NNS from_IN four_CD independent_JJ trials_NNS using_VBG naive_JJ CTL_NP ranged_VBD between_IN 79_CD and_CC 99_CD muM_NN (_( mean_VB ,_, 87.5_CD muM_NN )_) ZDV_NP (_( Table_NP ,_, Arm_NP 1_CD )_) ._SENT By_IN comparison_NN ,_, the_DT IC50_NP values_NNS for_IN the_DT four_CD trials_NNS with_IN double-prime_NP CTL_NP ranged_VBD between_IN 62_CD and_CC 638_CD muM_NN (_( mean_VB ,_, 316_CD muM_NN )_) ZDV_NP (_( Table_NP ,_, Arm_NP 2_CD )_) ._SENT However_RB ,_, when_WRB the_DT antigen-primed_JJ C57BL6_NP CTL_NP were_VBD cultured_VBN with_IN syngeneic_JJ irradiated_JJ C57BL6_NP feeder_NN cells_NNS (_( prime/hold_NN )_) instead_RB of_IN the_DT double-prime_NN exposure_NN ,_, they_PP were_VBD found_VBN to_TO be_VB profoundly_RB sensitive_JJ to_TO ZDV_NP inhibition_NN ,_, with_IN IC50_NP values_NNS ranging_VBG from_IN 29_CD to_TO 30_CD muM_NN (_( mean_VB ,_, 29.6_CD muM_NN )_) ZDV_NP (_( Table_NP ,_, Arm_NP 3_CD )_) ._SENT ZDV_NP exposure_NN of_IN CTL_NP during_IN primary_JJ antigen_NN stimulation_NN does_VBZ not_RB select_VB for_IN a_DT more_JJR ZDV-resistant_NP CTL_NP population_NN ._SENT |_SYM The_DT IC50_JJ values_NNS of_IN alloantigen-primed_JJ effector_NN cells_NNS propagated_VBN in_IN the_DT presence_NN of_IN 80_CD muM_NN ZDV_NP were_VBD calculated_VBN to_TO determine_VB if_IN ZDV_NP treatment_NN during_IN antigen_NN priming_NN selected_VBN for_IN a_DT CTL_NP population_NN that_WDT was_VBD more_RBR resistant_JJ to_TO the_DT suppressive_JJ effects_NNS of_IN ZDV_NP ._SENT As_IN previously_RB observed_VBN ,_, the_DT number_NN of_IN cells_NNS collected_VBN at_IN the_DT end_NN of_IN the_DT 14-day_JJ incubation_NN period_NN in_IN the_DT cultures_NNS incubated_VBN with_IN ZDV_NP were_VBD substantially_RB less_JJR than_IN those_DT collected_VBN from_IN cultures_NNS without_IN ZDV_NP (_( data_NN not_RB shown_VBN )_) ._SENT The_DT addition_NN of_IN ZDV_NP to_TO the_DT culture_NN system_NN during_IN the_DT original_JJ antigen_NN priming_NN period_NN did_VBD not_RB select_VB for_IN a_DT cell_NN population_NN with_IN increased_VBN resistance_NN to_TO ZDV_NP suppression_NN ._SENT In_IN each_DT of_IN the_DT six_CD paired_VBN trials_NNS where_WRB lymphocytes_NNS were_VBD primed_VBN in_IN the_DT presence_NN of_IN 80_CD muM_NN ZDV_NP (_( three_CD in_IN Arm_NP 4_CD and_CC three_CD in_IN Arm_NP 5_CD )_) ,_, the_DT IC50_NP values_NNS were_VBD the_DT same_JJ or_CC less_JJR than_IN the_DT IC50_NP values_NNS for_IN the_DT lymphocytes_NNS primed_VBN in_IN the_DT absence_NN of_IN ZDV_NP ._SENT It_PP is_VBZ clear_JJ from_IN these_DT assays_NNS that_DT preincubation_NN of_IN T_NN cells_NNS during_IN alloantigen_NN priming_NN did_VBD not_RB produce_VB a_DT more_RBR drug-resistant_JJ T-cell_NN population_NN ._SENT In_IN summary_NN ,_, effector_NN cells_NNS which_WDT were_VBD alloantigen_NN primed_VBN for_IN 14_CD days_NNS but_CC not_RB restimulated_JJ with_IN DBA-2_NP alloantigen_NN during_IN the_DT IC50_NP assay_NN (_( incubated_VBN with_IN the_DT irradiated_JJ C57BL6_NP feeder_NN cell_NN layer_NN )_) were_VBD most_RBS sensitive_JJ to_TO ZDV_NP ,_, independent_JJ of_IN the_DT concentration_NN of_IN ZDV_NP they_PP encountered_VBD during_IN the_DT priming_NN period_NN ._SENT Unprimed_JJ lymphocytes_NNS ranked_VBD second_JJ in_IN sensitivity_NN ,_, followed_VBN by_IN alloantigen-primed_JJ and_CC restimulated_JJ effector_NN cells_NNS when_WRB treated_VBN with_IN ZDV_NP during_IN the_DT priming_NN phase_NN ._SENT Alloantigen-primed_JJ and_CC restimulated_JJ effector_NN cells_NNS not_RB treated_VBN with_IN ZDV_NP during_IN the_DT priming_NN phase_NN were_VBD significantly_RB less_RBR sensitive_JJ to_TO ZDV_NP suppression_NN than_IN unprimed_JJ or_CC primed_VBN cells_NNS that_WDT did_VBD not_RB reencounter_VB the_DT antigen_NN ._SENT FIG._NN 2_CD ._SENT |_SYM IC50_NP assay_NN ._SENT IC50_JJ assay_NN ._SENT The_DT influence_NN of_IN ZDV_NP on_IN generation_NN of_IN alloreactive_JJ CTL_NP is_VBZ shown_VBN in_IN a_DT representative_JJ assay_NN using_VBG naive_JJ splenocytes_NNS ._SENT All_DT wells_NNS in_IN 96-well_NN culture_NN dishes_NNS received_VBD the_DT same_JJ number_NN of_IN responder_NN cells_NNS (_( C57BL6_NP )_) and_CC stimulator_NN cells_NNS (_( irrDBA-2_NN )_) ._SENT ZDV_NP was_VBD present_NN in_RB replicates_VBZ of_IN six_CD at_IN the_DT indicated_JJ concentrations_NNS during_IN the_DT 7-day_JJ culture_NN period_NN ._SENT CTL_NP were_VBD measured_VBN by_IN 51Cr_NP release_NN ._SENT The_DT upper_JJ horizontal_JJ line_NN represents_VBZ the_DT mean_JJ total_JJ release_NN ,_, while_IN the_DT lower_JJR horizontal_NN line_NN represents_VBZ mean_VB spontaneous_JJ release_NN from_IN control_NN cultures_NNS ._SENT TABLE_NN 1_CD |_SYM Effect_NN of_IN alloantigen_NN priming_NN on_IN the_DT IC50_NN of_IN ZDV-mediated_JJ reduction_NN of_IN CTL_NP function_VBP Recognized_JJ limitations_NNS of_IN ZDV_NP antiviral_JJ therapy_NN are_VBP the_DT clinical_JJ side_NN effects_NNS and_CC the_DT development_NN of_IN drug_NN resistance_NN ._SENT In_IN addition_NN ,_, both_CC in_IN vitro_NN and_CC in_IN vivo_JJ studies_NNS have_VBP documented_VBN that_IN cells_NNS of_IN the_DT immune_JJ system_NN are_VBP sensitive_JJ to_TO therapeutic_JJ concentrations_NNS of_IN ZDV_NP ._SENT Evaluation_NN of_IN immunomodulation_NN by_IN antiviral_JJ drugs_NNS on_IN lymphocyte_NN effector_NN cell_NN functions_NNS may_MD be_VB crucial_JJ because_IN drug-induced_JJ interference_NN of_IN immune_JJ function_NN ,_, already_RB impaired_VBN by_IN virus_NN infection_NN ,_, may_MD potentially_RB reduce_VB even_RB further_RBR the_DT capacity_NN to_TO respond_VB to_TO the_DT infection_NN ._SENT We_PP previously_RB demonstrated_VBD a_DT dose-dependent_JJ inhibition_NN of_IN CTL_NP clonal_JJ expansion_NN by_IN ZDV_NP in_IN an_DT in_IN vitro_NP alloantigenic_JJ murine_JJ system_NN ._SENT In_IN the_DT work_NN described_VBD here_RB ,_, using_VBG the_DT same_JJ alloantigen_NN system_NN ,_, we_PP have_VBP introduced_VBN a_DT statistical_JJ method_NN to_TO determine_VB the_DT IC50_NP of_IN ZDV_NP on_IN antigen-specific_JJ cytotoxic_JJ T-cell_NN clonal_JJ expansion_NN ._SENT Based_VBN on_IN previous_JJ observations_NNS by_IN ourselves_PP and_CC others_NNS ,_, we_PP hypothesized_VBD that_IN the_DT sensitivity_NN of_IN T_NN lymphocytes_NNS to_TO the_DT suppressive_JJ effects_NNS of_IN ZDV_NP depends_VBZ on_IN the_DT activation_NN status_NN of_IN those_DT cells_NNS (_( naive_JJ versus_IN antigen_NN primed_VBN )_) ._SENT Our_PP$ results_NNS revealed_VBD that_IN 80_CD to_TO 100_CD muM_NN ZDV_NP reduced_VBD the_DT capacity_NN of_IN naive_JJ splenocytes_NNS to_TO become_VB CTL_NP effector_NN cells_NNS by_IN one-half_JJ (_( mean_JJ IC50_NN =_SYM 87.5_CD muM_NN )_) ._SENT By_IN contrast_NN ,_, antigen-primed_JJ lymphocytes_NNS with_IN continuous_JJ exposure_NN to_TO allogeneic_JJ cells_NNS (_( double_RB prime_JJ )_) were_VBD substantially_RB more_RBR resistant_JJ to_TO the_DT suppressive_JJ effects_NNS of_IN ZDV_NP (_( mean_NN IC50_NP ,_, 316_CD muM_NN )_) ._SENT Antigen-primed_JJ CTLs_NNS differ_VBP from_IN their_PP$ naive_JJ precursors_NNS in_IN many_JJ regards_NNS ,_, including_VBG morphology_NN ,_, surface_NN antigen_NN expression_NN ,_, and_CC responsiveness_NN to_TO antigen_NN reexposure_NN and_CC cytokine_NN expression_NN ,_, e.g._FW ,_, IL-2_NP ._SENT It_PP is_VBZ known_VBN that_IN antigen-activated_JJ murine_JJ CTL_NP do_VBP not_RB require_VB additional_JJ contact_NN with_IN stimulatory_JJ antigen_NN for_IN continued_JJ clonal_JJ expansion_NN but_CC respond_VB to_TO mitogenic_JJ lymphokines_NNS for_IN a_DT defined_VBN time_NN period_NN after_IN antigen_NN contact_NN ._SENT Therefore_RB ,_, substituting_VBG syngeneic_JJ irradiated_JJ C57BL6_NP splenocytes_NNS as_IN feeder_NN cells_NNS for_IN alloantigenic_JJ DBA-2_NP splenocytes_NNS during_IN the_DT IC50_NP assay_NN following_VBG antigen_NN priming_VBG permitted_VBN evaluation_NN of_IN cytolytic_JJ precursors_NNS which_WDT became_VBD activated_VBN during_IN the_DT primary_JJ antigen_NN encounter_NN (_( first_RB 14_CD days_NNS of_IN culture_NN )_) ._SENT By_IN contrast_NN ,_, cultures_NNS which_WDT were_VBD primed_VBN during_IN the_DT first_JJ 14_CD days_NNS and_CC were_VBD reexposed_VBN to_TO alloantigen_NN during_IN the_DT inhibition_NN assay_NN allowed_VBD detection_NN of_IN both_DT primed_VBN effector_NN cells_NNS and_CC antigen-specific_JJ precursors_NNS which_WDT were_VBD not_RB stimulated_VBN during_IN the_DT first_JJ antigen_NN exposure_NN ._SENT With_IN this_DT in_IN mind_NN ,_, we_PP found_VBD that_IN alloantigen-primed_JJ lymphocytes_NNS ,_, reexposed_VBN to_TO the_DT same_JJ antigen_NN (_( double_RB prime_JJ )_) ,_, were_VBD less_RBR sensitive_JJ to_TO the_DT suppressive_JJ effects_NNS of_IN ZDV_NP (_( higher_JJR IC50_NN )_) than_IN primed_VBN cells_NNS not_RB reexposed_VBN to_TO antigen_NN (_( prime/hold_NN )_) ._SENT Since_IN the_DT maintenance_NN of_IN antigen-primed_JJ but_CC nonrestimulated_JJ effector_NN cells_NNS is_VBZ mainly_RB dependent_JJ on_IN IL-2_JJ utilization_NN ,_, ZDV_NP interference_NN with_IN either_DT receptor_NN expression_NN or_CC receptor-ligand_NN interaction_NN would_MD be_VB potential_JJ mechanisms_NNS explaining_VBG the_DT observed_JJ difference_NN in_IN sensitivity_NN ._SENT Exogenous_JJ IL-2_NP reverses_VBZ or_CC reduces_VBZ the_DT in_IN vitro_NP and_CC in_IN vivo_JJ suppressive_JJ effects_NNS of_IN ZDV_NP ,_, consistent_JJ with_IN this_DT hypothesis_NN ._SENT However_RB ,_, a_DT separate_JJ study_NN ,_, which_WDT specifically_RB evaluated_VBD cytokine_JJ production_NN by_IN lymphocytes_NNS from_IN HIV-positive_JJ patients_NNS during_IN ZDV_NP treatment_NN ,_, did_VBD not_RB reveal_VB reduced_VBN IL-2_JJ production_NN ,_, and_CC another_DT study_NN reported_VBD a_DT significant_JJ increase_NN in_IN IL-2_JJ receptor_NN (_( CD25_NP )_) expression_NN by_IN mitogen-stimulated_JJ T_NN lymphocytes_NNS from_IN ZDV-treated_NP AIDS_NP patients_NNS ._SENT Therefore_RB ,_, even_RB though_IN excess_JJ exogenous_JJ IL-2_NN was_VBD provided_VBN in_IN the_DT tissue_NN culture_NN medium_NN of_IN our_PP$ cultures_NNS during_IN the_DT antigen_NN priming_NN period_NN and_CC in_IN the_DT IC50_NP assay_NN ,_, we_PP cannot_MD exclude_VB the_DT possibility_NN that_IN ZDV_NP interfered_VBD with_IN cytokine-dependent_JJ T-cell-mediated_JJ helper_NN function_NN ._SENT We_PP further_RBR found_VBD that_IN 80_CD muM_NN ZDV_NP treatment_NN of_IN CTL_NP during_IN antigen_NN priming_NN had_VBD a_DT drug_NN concentration-related_JJ effect_NN on_IN the_DT number_NN of_IN cells_NNS harvested_VBN after_IN the_DT 14-day_JJ priming_NN period_NN (_( data_NNS not_RB shown_VBN )_) but_CC did_VBD not_RB affect_VB the_DT ZDV_NP IC50_NP values_VBZ of_IN progeny_NN cells_NNS compared_VBN to_TO non-ZDV-treated_JJ cells_NNS ._SENT This_DT observation_NN was_VBD independent_JJ of_IN the_DT type_NN of_IN antigen_NN (_( syngeneic_JJ or_CC allogeneic_JJ )_) used_VBN during_IN the_DT culture_NN period_NN ._SENT We_PP had_VBD previously_RB shown_VBN that_IN the_DT concentration-response-related_JJ reduction_NN of_IN effector_NN cells_NNS harvested_VBD following_VBG priming_NN in_IN the_DT presence_NN of_IN ZDV_NP was_VBD most_RBS likely_RB mediated_VBN by_IN reduced_VBN clonal_JJ expansion_NN of_IN alloantigen-stimulated_JJ effector_NN cells_NNS ._SENT However_RB ,_, based_VBN on_IN the_DT present_JJ study_NN ,_, it_PP appears_VBZ that_IN previous_JJ antigen_NN exposure_NN rendered_VBD the_DT effector_NN cell_NN more_RBR sensitive_JJ to_TO the_DT suppressive_JJ effects_NNS of_IN ZDV_NP (_( prime/hold_NN study_NN )_) ._SENT This_DT sensitivity_NN was_VBD altered_VBN by_IN a_DT second_JJ antigen_NN encounter_NN ._SENT Both_CC in_IN vitro_NN and_CC in_IN vivo_JJ studies_NNS suggest_VBP that_IN the_DT initial_JJ antigen-priming_NN period_NN is_VBZ the_DT most_RBS sensitive_JJ to_TO interference_NN by_IN ZDV_NP and_CC other_JJ nucleoside_NN analogues_NNS ._SENT This_DT later_JJR finding_NN ,_, however_RB ,_, suggests_VBZ that_IN the_DT activational_JJ status_NN of_IN the_DT cell_NN exposed_VBN to_TO ZDV_NP is_VBZ crucially_RB important_JJ in_IN terms_NNS of_IN drug_NN sensitivity_NN and_CC is_VBZ independent_JJ of_IN previous_JJ drug_NN exposure_NN ._SENT The_DT double-primed_JJ cultures_NNS which_WDT were_VBD antigen_NN primed_VBN in_IN the_DT presence_NN of_IN 80_CD muM_NN ZDV_NP (_( Table_NP ,_, Arm_NP 4_CD )_) did_VBD not_RB develop_VB greater_JJR resistance_NN to_TO ZDV_NP than_IN paired_VBN double-primed_JJ cultures_NNS without_IN ZDV_NP (_( Table_NP ,_, Arm_NP 2_CD )_) ._SENT However_RB ,_, IC50_NP values_NNS from_IN the_DT double-prime_JJ ZDV_NP data_NNS set_VBN (_( Table_NP ,_, Arm_NP 4_CD )_) were_VBD variable_JJ ._SENT It_PP is_VBZ likely_JJ that_IN many_JJ of_IN the_DT precursor_NN T_NN cells_NNS capable_JJ of_IN responding_VBG to_TO DBA-2_NP antigen_NN were_VBD suppressed_VBN by_IN ZDV_NP during_IN the_DT first_JJ antigen_NN exposure_NN period_NN ,_, such_JJ that_IN they_PP failed_VBD to_TO respond_VB and_CC remained_VBD in_IN an_DT unprimed_JJ state_NN equivalent_NN to_TO naive_JJ CTLs_NNS ._SENT Thus_RB ,_, a_DT second_JJ round_NN of_IN antigen_NN exposure_NN may_MD have_VB stimulated_VBN a_DT disproportionate_JJ number_NN of_IN naive_JJ T_NN cells_NNS (_( Table_NP ,_, Arm_NP 4_CD )_) compared_VBN to_TO the_DT cultures_NNS which_WDT did_VBD not_RB have_VB ZDV_NP during_IN antigen_NN priming_NN (_( Table_NP ,_, Arm_NP 2_CD )_) ._SENT A_DT relatively_RB larger_JJR number_NN of_IN naive_JJ compared_VBN to_TO primed_VBN T_NN cells_NNS responding_VBG in_IN these_DT cultures_NNS could_MD reduce_VB the_DT IC50_NP value_NN ,_, since_IN naive_JJ cells_NNS are_VBP more_RBR sensitive_JJ to_TO ZDV_NP than_IN primed_VBN cells_NNS ,_, as_RB shown_VBN in_IN Table_NP ,_, Arm_NP 1_CD ._SENT In_IN addition_NN ,_, because_IN the_DT extent_NN of_IN primary_JJ antigen_NN stimulation_NN (_( percentage_NN of_IN precursors_NNS capable_JJ of_IN responding_VBG )_) may_MD vary_VB from_IN trial_NN to_TO trial_NN ,_, one_PP might_MD expect_VB variability_NN in_IN IC50_JJ values_NNS for_IN double-prime_JJ cultures_NNS (_( Table_NP ,_, Arms_NP 2_CD and_CC 4_CD )_) ._SENT In_IN the_DT single-prime_JJ cultures_NNS (_( prime/hold_NN )_) ,_, there_EX was_VBD no_DT opportunity_NN to_TO recruit_VB additional_JJ naive_JJ cells_NNS ,_, resulting_VBG in_IN a_DT more_RBR consistent_JJ response_NN between_IN either_DT ZDV-treated_JJ or_CC untreated_JJ cultures_NNS (_( Table_NP ,_, Arms_NP 3_CD and_CC 5_CD )_) ._SENT Further_RBR ,_, because_IN the_DT cell_NN concentrations_NNS were_VBD adjusted_VBN after_IN primary_JJ antigen_NN stimulation_NN (_( with_IN or_CC without_IN ZDV_NP )_) ,_, both_CC cultures_NNS were_VBD presumably_RB the_DT same_JJ in_IN terms_NNS of_IN the_DT number_NN of_IN potential_JJ effector_NN cells_NNS ._SENT In_IN the_DT subsequent_JJ 7-day_JJ culture_NN period_NN ,_, both_DT prime/hold_NN and_CC double-prime_NN cultures_NNS received_VBD IL-2-containing_JJ medium_NN ,_, which_WDT promoted_VBD proliferation_NN of_IN primed_VBN cells_NNS but_CC not_RB naive_JJ cells_NNS ._SENT Because_IN the_DT single-primed_JJ effector_NN cells_NNS (_( prime/hold_NN )_) from_IN both_CC the_DT ZDV-treated_JJ and_CC untreated_JJ cultures_NNS gave_VBD essentially_RB identical_JJ IC5o_NP values_NNS (_( Table_NP ,_, Arms_NP 3_CD and_CC 5_CD )_) ,_, it_PP appeared_VBD that_IN ZDV_NP treatment_NN during_IN priming_NN had_VBD no_DT propensity_NN to_TO increase_VB T-cell_NN resistance_NN to_TO ZDV_NP suppression_NN ._SENT The_DT mechanism_NN by_IN which_WDT ZDV_NP suppresses_VBZ CTL_NP leading_VBG to_TO variable_JJ IC50_NP values_NNS for_IN naive_JJ ,_, prime/hold_NN ,_, and_CC double-prime_NP CTL_NP is_VBZ not_RB known_VBN ._SENT Based_VBN on_IN previous_JJ studies_NNS ,_, it_PP is_VBZ assumed_VBN that_IN ZDV_NP suppresses_VBZ clonal_JJ expansion_NN of_IN antigen-stimulated_JJ CTL_NP ._SENT ZDV_NP has_VBZ been_VBN shown_VBN to_TO prolong_VB mitosis_NN ,_, inhibit_VBP mitochondrial_JJ DNA_NN polymerase_NN ,_, and_CC deplete_VB the_DT TTP_NP pool_NN ,_, all_DT of_IN which_WDT affect_VBP cell_NN proliferation_NN ._SENT In_IN our_PP$ previous_JJ studies_NNS ,_, we_PP found_VBD ZDV_NP to_TO be_VB cytostatic_JJ at_IN concentrations_NNS ranging_VBG between_IN 15_CD and_CC 250_CD muM_NN and_CC cytotoxic_JJ at_IN concentrations_NNS of_IN 500_CD muM_NN or_CC greater_JJR when_WRB tested_VBN on_IN naive_JJ lymphocyte_NN cultures_NNS ._SENT These_DT results_NNS were_VBD gathered_VBN using_VBG the_DT same_JJ C57BL6/DBA-2_NP alloantigen_NN model_NN ._SENT We_PP also_RB observed_VBD that_IN a_DT delay_NN in_IN the_DT addition_NN of_IN ZDV_NP reduced_VBD its_PP$ suppressive_JJ effect_NN in_IN vitro_NN and_CC in_IN vivo_RB ,_, allowing_VBG more_JJR effector_NN cells_NNS to_TO be_VB produced_VBN ._SENT Tissue_NN culture_NN cell_NN lines_NNS as_RB well_RB as_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS (_( PBMC_NP )_) grown_VBN long-term_JJ in_IN the_DT presence_NN of_IN ZDV_NP become_VBP resistant_JJ to_TO ZDV_NP antiviral_JJ activity_NN by_IN decreasing_VBG the_DT concentration_NN of_IN thymidine_NN kinase_NN (_( TK_NP )_) ,_, a_DT crucial_JJ enzyme_NN necessary_JJ for_IN the_DT phosphorylation_NN of_IN ZDV_NP to_TO ZDV-monophosphate_NP (_( ZDV-MP_NP )_) ._SENT The_DT failure_NN of_IN the_DT phosphorylation_NN cascade_NN necessary_JJ to_TO convert_VB ZDV_NP to_TO its_PP$ active_JJ anabolite_NN ,_, ZDV-triphosphate_NP (_( ZDV-TP_NP )_) ,_, renders_VBZ the_DT cells_NNS less_RBR sensitive_JJ to_TO the_DT antiviral_JJ activity_NN of_IN ZDV_NP and_CC less_RBR sensitive_JJ to_TO the_DT toxic_JJ effects_NNS of_IN ZDV_NP caused_VBD by_IN the_DT ZDV-MP_NP intermediate_NN ._SENT Reduced_VBN TK_NP expression_NN in_IN ZDV-resistant_NP Jurkat_NP T_NN cells_NNS has_VBZ been_VBN linked_VBN to_TO methylation_NN of_IN the_DT human_JJ TK_NP gene_NN ._SENT The_DT observation_NN that_IN PBMC_NP from_IN HIV-infected_JJ patients_NNS on_IN long-term_JJ ZDV_NP have_VBP reduced_VBN TK_NP is_VBZ suggestive_JJ that_IN ZDV_NP modulates_VBZ TK_NP expression_NN ._SENT However_RB ,_, a_DT more_RBR likely_JJ explanation_NN is_VBZ that_IN ZDV_NP therapy_NN selects_VBZ for_IN a_DT T-cell_NN population_NN of_IN naturally_RB low_JJ expressors_NNS of_IN TK_NP ._SENT Phytohemagglutinin-stimulated_JJ human_JJ PBMC_NN have_VBP higher_JJR TK_NP expression_NN and_CC greater_JJR sensitivity_NN to_TO ZDV_NP inhibition_NN of_IN HIV-1_JJ infection_NN than_IN nonstimulated_JJ controls_NNS ._SENT These_DT cells_NNS are_VBP likely_JJ to_TO be_VB more_RBR sensitive_JJ to_TO the_DT cytostatic_JJ and_CC cytotoxic_JJ effects_NNS of_IN ZDV_NP (_( low_JJ IC50_NN )_) ._SENT This_DT latter_JJ observation_NN is_VBZ counter_JJ to_TO our_PP$ work_NN ,_, where_WRB highly_RB activated_VBN T_NN cells_NNS (_( double_RB prime_JJ )_) had_VBD greater_JJR resistance_NN to_TO ZDV_NP toxicity_NN ._SENT An_DT alternative_JJ explanation_NN for_IN increased_VBN resistance_NN to_TO ZDV_NP by_IN activated_VBN T_NN cells_NNS is_VBZ increased_VBN expression_NN of_IN the_DT multidrug-resistant_JJ (_( MDR_NP )_) transmembrane_NP P-glycoprotein_NP (_( p170_NN )_) ,_, which_WDT acts_VBZ as_IN an_DT efflux_NN pump_NN to_TO remove_VB intracellular_JJ ions_NNS ,_, toxins_NNS ,_, and_CC drugs_NNS ,_, rendering_VBG the_DT cell_NN resistant_JJ to_TO the_DT cytostatic_JJ and_CC cytotoxic_JJ effects_NNS of_IN ZDV_NP ._SENT In_IN normal_JJ human_JJ PBMC_NP ,_, the_DT majority_NN of_IN CD8+_NP T_NN cells_NNS ,_, but_CC less_JJR than_IN half_NN of_IN the_DT CD4+_NP T-cell_NN population_NN ,_, express_JJ p170_NN ._SENT Interestingly_RB ,_, phytohemagglutinin_NN stimulation_NN of_IN human_JJ PBMC_NP causes_VBZ an_DT increase_NN in_IN p170_NN by_IN the_DT CD8+_NP T-cell_NN subset_NN ,_, and_CC anti-p170_JJ blocks_NNS the_DT cytolytic_JJ activity_NN of_IN alloantigen-specific_JJ cytotoxic_JJ T_NN cells_NNS ._SENT A_DT natural_JJ function_NN of_IN p170_NN may_MD be_VB in_IN aiding_VBG the_DT secretion_NN of_IN certain_JJ cytokines_NNS ._SENT Taken_VBN together_RB ,_, it_PP appears_VBZ that_IN p170_NN expression_NN is_VBZ easily_RB modulated_VBN by_IN immune_JJ stimulation_NN and_CC may_MD play_VB an_DT important_JJ role_NN in_IN cytotoxic_JJ T-cell_NN effector_NN cell_NN function_NN ._SENT The_DT upregulation_NN of_IN p170_NN by_IN antigen-stimulated_JJ T_NN cells_NNS ,_, as_IN a_DT mechanism_NN for_IN increased_VBN drug_NN resistance_NN ,_, would_MD be_VB compatible_JJ with_IN our_PP$ double-prime_JJ stimulation_NN results_NNS ._SENT Further_JJR studies_NNS will_MD be_VB needed_VBN to_TO document_VB the_DT full_JJ range_NN of_IN p170_JJ expression_NN in_IN the_DT different_JJ activation_NN stages_NNS of_IN cytotoxic_JJ T_NN cells_NNS and_CC to_TO correlate_VB those_DT results_NNS with_IN drug_NN sensitivity_NN ._SENT Determining_VBG the_DT relevance_NN of_IN this_DT work_NN to_TO the_DT plasma_NN ZDV_NP concentrations_NNS of_IN humans_NNS on_IN ZDV_NP therapy_NN is_VBZ made_VBN difficult_JJ by_IN the_DT species_NN differences_NNS in_IN ZDV_NP processing_NN ._SENT Mouse_NP lymphoid_JJ cells_NNS form_VBP ZDV-TP_NP at_IN a_DT level_NN 16_CD times_NNS higher_JJR than_IN that_IN of_IN human_JJ lymphoid_JJ cells_NNS ._SENT Human_JJ lymphoid_JJ cells_NNS were_VBD reportedly_RB 15_CD times_NNS more_RBR sensitive_JJ to_TO the_DT cytostatic_JJ effects_NNS of_IN ZDV_NP and_CC dideoxycytosine_NP than_IN were_VBD mouse_NN lymphoid_JJ cells_NNS ._SENT The_DT high_JJ level_NN of_IN ZDV-MP_NP formed_VBD in_IN human_JJ lymphoid_JJ cells_NNS ,_, which_WDT is_VBZ known_VBN to_TO inhibit_VB thymidylate_JJ kinase_NN and_CC adenylate_JJ kinase_NN ,_, may_MD account_VB for_IN the_DT cytostatic_JJ effect_NN of_IN ZDV_NP ._SENT Therefore_RB ,_, studies_NNS in_IN mouse_NN systems_NNS may_MD underestimate_VB the_DT true_JJ cytostatic_JJ effect_NN of_IN ZDV_NP treatment_NN in_IN human_JJ cells_NNS by_IN a_DT factor_NN of_IN 15_CD ._SENT The_DT concentration_NN of_IN ZDV_NP found_VBD to_TO suppress_VB the_DT CTL_NP response_NN of_IN mouse_NN splenocytes_NNS by_IN 50_CD %_NN ranged_VBN between_IN approximately_RB 30_CD and_CC >600_JJ muM_NN ,_, while_IN the_DT peak_JJ ZDV_NP concentration_NN in_IN patients_NNS receiving_VBG the_DT recommended_JJ ZDV_NP dosage_NN has_VBZ been_VBN calculated_VBN to_TO be_VB in_IN the_DT range_NN of_IN 3_CD to_TO 7_CD muM_NN ._SENT Assuming_VBG the_DT 15-fold_NN difference_NN between_IN mice_NNS and_CC human_JJ cells_NNS ,_, one_PP might_MD predict_VB that_DT human_JJ naive_JJ T_NN cells_NNS would_MD be_VB suppressed_VBN by_IN ZDV_NP concentrations_NNS as_IN low_JJ as_IN 2_CD muM_NN ,_, well_RB within_IN the_DT human_JJ peak_NN plasma_NN drug_NN concentration_NN ._SENT These_DT assumptions_NNS ,_, however_RB ,_, are_VBP based_VBN on_IN predicted_VBN behavior_NN of_IN human_JJ lymphocytes_NNS and_CC not_RB actual_JJ T-cell_NN response_NN data_NNS ._SENT The_DT IC50_NP assay_NN used_VBN in_IN a_DT mouse_NN alloantigen_NN model_NN will_MD be_VB a_DT useful_JJ tool_NN for_IN testing_VBG the_DT drug_NN sensitivity_NN of_IN human_JJ T-cell_NN responses_NNS to_TO HIV_NP antigens_NNS ._SENT Taken_VBN together_RB ,_, our_PP$ studies_NNS show_VBP that_IN ZDV_NP reduced_VBD cytolytic_JJ effector_NN cell_NN function_NN in_IN a_DT concentration-dependent_JJ manner_NN and_CC suggest_VBP that_IN alloantigen-primed_JJ effector_NN cells_NNS ,_, when_WRB not_RB given_VBN continuous_JJ exposure_NN or_CC rescued_VBD by_IN a_DT second_JJ antigen_NN encounter_NN ,_, are_VBP more_RBR sensitive_JJ to_TO ZDV_NP suppression_NN than_IN naive_JJ cells_NNS ._SENT This_DT observation_NN may_MD have_VB relevance_NN in_IN persons_NNS with_IN HIV_NP ,_, where_WRB a_DT strong_JJ CTL_NP immune_JJ response_NN is_VBZ critical_JJ for_IN the_DT prevention_NN of_IN disease_NN progression_NN ._SENT Administration_NN of_IN ZDV_NP and_CC possibly_RB other_JJ nucleoside_NN analogues_NNS during_IN the_DT time_NN of_IN initial_JJ antigen_NN priming_NN of_IN T_NN cells_NNS may_MD reduce_VB the_DT peak_JJ CTL_NP response_NN to_TO virus_NN ._SENT Possible_JJ drug_NN interference_NN with_IN immune_JJ function_NN should_MD be_VB considered_VBN when_WRB determining_VBG drug_NN dosage_NN and_CC the_DT time_NN point_NN of_IN ZDV_NP treatment_NN initiation_NN ._SENT 